David C. Underwood

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung

David C. Underwood, Ruth R. Osborn, Steven Bochnowicz et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2000 · 297 citations

Asthma, Antifibrotic Therapy, Inflammatory Lung Disease +23

SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence

David C. Underwood, Ruth R. Osborn, Charles J. Kotzer et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 244 citations

Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models

Robert S. Ames, Dennis Lee, James J. Foley et al. · The Journal of Immunology · 2001 · 200 citations · Full text

Immunology, Competitive Antagonist, Immunologic Mechanism +18

1,4-Cyclohexanecarboxylates:  Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of Asthma

Siegfried B. Christensen, Aimee M. Guider, Cornelia J. Forster et al. · Journal of Medicinal Chemistry · 1998 · 150 citations · Full text

Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody.

David C. Underwood, Ruth R. Osborn, S J Newsholme et al. · American Journal of Respiratory and Critical Care Medicine · 1996 · 141 citations

Inflammation, Asthma, Inflammatory Lung Disease +14